TUDCA Side Effects & Safety: What the Research Shows

TUDCA has a generally favorable short-term safety profile based on published clinical data. However, the evidence base is narrower than for UDCA, and there are specific safety gaps that anyone considering TUDCA should understand. This page summarizes adverse event data from published human studies and addresses the limits of current safety knowledge.

1. Most Common Side Effects

Diarrhea is the most frequently reported side effect of TUDCA, and it is dose-dependent. At the standard supplement dose of 250–500 mg/day, diarrhea occurs in approximately 5–10% of users based on adverse event reporting in clinical studies. At doses of 1,500–2,000 mg/day (as used in the ALS pilot trial and metabolic studies), diarrhea rates increase to 15–25%.

The mechanism of TUDCA-associated diarrhea is primarily osmotic: as a bile acid, TUDCA draws water into the intestinal lumen when present in high concentrations in the colon, increasing stool water content and accelerating transit time. This is the same mechanism that causes diarrhea with UDCA and other bile acid-based therapies. Reducing the dose or dividing it into 2–3 smaller administrations with meals typically resolves mild-to-moderate diarrhea.

Other reported gastrointestinal side effects, occurring at rates below 5% in clinical studies, include abdominal discomfort, nausea, bloating, and dyspepsia. These also tend to be dose-related and transient during the first week of supplementation.

2. Safety in Clinical Trials

Safety data from published clinical trials of TUDCA include:

• ALS pilot trial (Elia et al., 2016) and Phase 3 (TUDCA-ALS, 2024): In the pilot (n=34), 1 g twice daily for 54 weeks was well-tolerated with no SAEs attributed to TUDCA. The Phase 3 trial (n=336, 18 months) confirmed tolerability — predominantly mild GI adverse events across both treatment and placebo arms — but did not meet its primary efficacy endpoint.
• Metabolic study (Kars et al., 2010): 20 obese subjects received TUDCA 1,750 mg/day for 4 weeks. No clinically significant changes in liver function tests, renal function, or blood counts were observed relative to placebo. Mild gastrointestinal symptoms were reported by 30% of TUDCA recipients vs. 10% of placebo recipients.
• Liver disease trials (various, open-label): Across multiple small studies of TUDCA in chronic hepatitis (3–6 months duration), serious adverse events have not been reported. The side effect profile is consistent with gastrointestinal symptoms at a frequency of 10–20%.

The total number of human subjects who have received TUDCA in published clinical trials is fewer than 200, and no study has exceeded 54 weeks. This is a small safety database relative to pharmaceutical standards.

3. Who Should NOT Take TUDCA

TUDCA is contraindicated in the following situations:

• Complete biliary obstruction: TUDCA stimulates bile flow. In a fully obstructed biliary tree, choleresis increases intraductal pressure, which can cause pain and worsen cholestatic injury. This contraindication applies to UDCA as well and is standard for all choleretic agents.
• Known hypersensitivity to bile acids: Allergic reactions to bile acid preparations are rare but documented in the UDCA literature. Cross-reactivity between UDCA and TUDCA is likely given their structural similarity.
• Acute cholecystitis or cholangitis: TUDCA should not be initiated during acute biliary tract infections or inflammation. It may be used after resolution if indicated for underlying cholestatic disease.
• Pregnancy and lactation: No adequate human studies exist. In animal reproduction studies, UDCA at high doses showed no teratogenicity, but TUDCA-specific reproductive toxicology data are not published. The risk-benefit ratio cannot be assessed without data.
• Pediatric populations: Safety and efficacy have not been established in children. UDCA is used off-label in pediatric cholestatic disorders, but TUDCA use in children is not supported by published data.

4. Long-Term Safety

The most significant gap in TUDCA's safety profile is the absence of long-term safety data. The longest published human study is 54 weeks (the ALS pilot trial). There are no multi-year TUDCA cohorts comparable to the decades of data available for UDCA. Key unknowns include:

• Carcinogenicity: No animal carcinogenicity studies of TUDCA have been published. UDCA has not shown carcinogenic potential in standard assays, and TUDCA is a natural bile acid conjugate, which argues against carcinogenicity. However, colon cancer risk with long-term bile acid supplementation remains a theoretical concern — secondary bile acids (deoxycholic acid, lithocholic acid) are established tumor promoters in colorectal cancer models.
• Hepatotoxicity: While TUDCA is hepatoprotective in the short term, the long-term hepatic effect of supraphysiologic TUDCA exposure is uncharacterized. UDCA at very high doses (>30 mg/kg/day) has been associated with adverse hepatic outcomes in some PBC studies. Whether TUDCA has a similar ceiling is unknown.
• Cardiovascular outcomes: Bile acid signaling influences lipid metabolism and atherosclerosis. Long-term modulation of the bile acid pool by exogenous TUDCA has not been studied for cardiovascular endpoints.

5. Drug Interactions

Published drug interaction studies for TUDCA are essentially nonexistent. Based on TUDCA's pharmacology and data from the structurally related UDCA, the following theoretical interactions warrant caution:

• Bile acid sequestrants (cholestyramine, colestipol, colesevelam): These bind TUDCA in the intestinal lumen, preventing absorption. Separate dosing by at least 4 hours.
• Aluminum-based antacids: Aluminum hydroxide can bind bile acids, reducing TUDCA bioavailability. Separate dosing by at least 2 hours.
• Cyclosporine: UDCA has been reported to increase cyclosporine absorption in some transplant patients. Whether TUDCA has the same effect is unknown, but the mechanism may be shared.
• CYP3A4 substrates: Bile acids modulate CYP450 enzyme expression through FXR and PXR nuclear receptors. TUDCA's effects on CYP enzyme activity have not been characterized, so interactions with CYP3A4-metabolized drugs (statins, calcium channel blockers, some anticoagulants) cannot be ruled out.

6. When to Consult a Physician

Anyone considering TUDCA should consult a licensed healthcare provider in the following scenarios: (1) pre-existing liver, gallbladder, or biliary tract disease, (2) concurrent use of prescription medications that are CYP3A4 substrates or drugs with narrow therapeutic indices, (3) pregnancy, planned pregnancy, or breastfeeding, (4) persistent diarrhea lasting more than 3 days after starting TUDCA, (5) known bile acid metabolism disorder, and (6) any unexplained symptom that develops after starting TUDCA supplementation.

TUDCA is a biologically active compound, not a food. Its use should be treated with the same risk-awareness as any supplement with pharmacological effects.

Related Articles

References

1. Elia AE, Lalli S, Monsurro MR, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016;23(1):45-52.
2. Kars M, Yang L, Gregor MF, et al. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010;59(8):1899-1905.
3. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest. 1998;101(12):2790-2799.
4. Vang S, Longley K, Steer CJ, Low WC. The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases. Glob Adv Health Med. 2014;3(3):58-69.